The phase 1 clinical trial will test the feasibility and safety of CAR-T cells - genetically modified white blood cells harvested from a patient's own blood with the unique ability to directly attack and kill cancers - to treat advanced solid tumors including small cell lung cancer, sarcomas and triple negative breast cancer.
More...